Oncolytics Biotech Inc. ONCY
0.39 USD -0.05 (-11.29%)
Regular-session close
0.38 -0.01 -1.66%
After hours · Nov 19, 6:51 PM ET
0.39 Day range 0.46
0.33 52-week range 1.30
- YTD
- -55.10%
- 1 year
- -62.44%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.
globenewswire.com Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcibenzinga.com Oncolytics Biotech Announces New Translational Data From An Ongoing Study Showing Pelareorep’s Ability To Increase HPV-16-Specific T Cell Clones And Tumor-Infiltrating Lymphocyte Clones In Second-Line Or Later Squamous Cell Anal Cancer Patients; Immune Activation Levels More Than Doubled In Nearly All Patients After One Cycle Of Treatment; Substantial Increases In HPV-16-Specific T Cells And Tumor-Infiltrating Lymphocytes Observed When Pelareorep Is Combined With A Checkpoint Inhibitor Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced new translational data from an ongoing study…
benzinga.com Oncolytics Biotech Announces Its Group 4 Of Phase 1/2 GOBLET Trial Of Pelareorep In Combination With Atezolizumab Failed to Reach Median Overall Survival Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updated data from Cohort 4 of its Phase 1/2 GOBLET
benzinga.com Oncolytics Biotech To Present Trail-In-Progress Abstract, E-Poster For Its REO 033 Trial At European Society For Medical Oncology Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the Company is presenting a trial-in-progress
